These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 9867188

  • 1. Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms.
    Derwahl M, Manole D, Sobke A, Broecker M.
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 4():S6-9. PubMed ID: 9867188
    [Abstract] [Full Text] [Related]

  • 2. [Mutations in the thyrotropin receptor gene in the pathogenesis of toxic thyroid adenomas, toxic goiter nodules and autosomal dominant hyperthyroidism].
    Derwahl M.
    Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():25-8. PubMed ID: 10355046
    [Abstract] [Full Text] [Related]

  • 3. [Molecular aspects in the pathogenesis of nodules and adenomas of the thyroid gland].
    Derwahl M.
    Schweiz Med Wochenschr; 1994 Sep 17; 124(37):1613-8. PubMed ID: 7939528
    [Abstract] [Full Text] [Related]

  • 4. Molecular aspects of the pathogenesis of nodular goiters, thyroid nodules and adenomas.
    Derwahl M.
    Exp Clin Endocrinol Diabetes; 1996 Sep 17; 104 Suppl 4():32-5. PubMed ID: 8980997
    [Abstract] [Full Text] [Related]

  • 5. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism.
    Paschke R.
    Exp Clin Endocrinol Diabetes; 1996 Sep 17; 104 Suppl 4():129-32. PubMed ID: 8981020
    [Abstract] [Full Text] [Related]

  • 6. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma.
    Tonacchera M, Chiovato L, Pinchera A, Agretti P, Fiore E, Cetani F, Rocchi R, Viacava P, Miccoli P, Vitti P.
    J Clin Endocrinol Metab; 1998 Feb 17; 83(2):492-8. PubMed ID: 9467563
    [Abstract] [Full Text] [Related]

  • 7. Somatic mutations in thyroid nodular disease.
    Krohn K, Paschke R.
    Mol Genet Metab; 2002 Mar 17; 75(3):202-8. PubMed ID: 11914031
    [Abstract] [Full Text] [Related]

  • 8. Hot microscopic areas of iodine-deficient euthyroid goitres contain constitutively activating TSH receptor mutations.
    Krohn K, Wohlgemuth S, Gerber H, Paschke R.
    J Pathol; 2000 Sep 17; 192(1):37-42. PubMed ID: 10951398
    [Abstract] [Full Text] [Related]

  • 9. Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas.
    Derwahl M, Hamacher C, Russo D, Broecker M, Manole D, Schatz H, Kopp P, Filetti S.
    J Clin Endocrinol Metab; 1996 May 17; 81(5):1898-904. PubMed ID: 8626855
    [Abstract] [Full Text] [Related]

  • 10. Gain of function TSH receptor mutations and iodine deficiency: implications in iodine prophylaxis.
    Tonacchera M, Vitti P, De Servi M, Agretti P, De Marco G, Chiovato L, Pinchera A.
    J Endocrinol Invest; 2003 May 17; 26(2 Suppl):2-6. PubMed ID: 12762632
    [Abstract] [Full Text] [Related]

  • 11. Enhanced functional activity in thyroid adenomas in vitro.
    Poertl S, Kirner J, Mann K, Hoermann R.
    Exp Clin Endocrinol Diabetes; 1996 May 17; 104 Suppl 4():39-40. PubMed ID: 8980999
    [Abstract] [Full Text] [Related]

  • 12. TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas--a note of caution.
    Derwahl M.
    J Clin Endocrinol Metab; 1996 Aug 17; 81(8):2783-5. PubMed ID: 8768829
    [Abstract] [Full Text] [Related]

  • 13. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter.
    Tonacchera M, Agretti P, Chiovato L, Rosellini V, Ceccarini G, Perri A, Viacava P, Naccarato AG, Miccoli P, Pinchera A, Vitti P.
    J Clin Endocrinol Metab; 2000 Jun 17; 85(6):2270-4. PubMed ID: 10852462
    [Abstract] [Full Text] [Related]

  • 14. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas.
    Parma J, Duprez L, Van Sande J, Hermans J, Rocmans P, Van Vliet G, Costagliola S, Rodien P, Dumont JE, Vassart G.
    J Clin Endocrinol Metab; 1997 Aug 17; 82(8):2695-701. PubMed ID: 9253356
    [Abstract] [Full Text] [Related]

  • 15. Thyrotropin receptor: a role for thyroid tumourigenesis?
    Russo D, Arturi F, Chiefari E, Filetti S.
    Forum (Genova); 1999 Aug 17; 9(2):166-75. PubMed ID: 10385711
    [Abstract] [Full Text] [Related]

  • 16. Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms.
    Tonacchera M, Vitti P, Agretti P, Ceccarini G, Perri A, Cavaliere R, Mazzi B, Naccarato AG, Viacava P, Miccoli P, Pinchera A, Chiovato L.
    J Clin Endocrinol Metab; 1999 Nov 17; 84(11):4155-8. PubMed ID: 10566665
    [Abstract] [Full Text] [Related]

  • 17. Autonomously functioning thyroid nodules in a former iodine-deficient area commonly harbor gain-of-function mutations in the thyrotropin signaling pathway.
    Georgopoulos NA, Sykiotis GP, Sgourou A, Papachatzopoulou A, Markou KB, Kyriazopoulou V, Papavassiliou AG, Vagenakis AG.
    Eur J Endocrinol; 2003 Oct 17; 149(4):287-92. PubMed ID: 14514342
    [Abstract] [Full Text] [Related]

  • 18. Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features.
    Arturi F, Capula C, Chiefari E, Filetti S, Russo D.
    Exp Clin Endocrinol Diabetes; 1998 Oct 17; 106(3):234-6. PubMed ID: 9710366
    [Abstract] [Full Text] [Related]

  • 19. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms.
    Matsuo K, Friedman E, Gejman PV, Fagin JA.
    J Clin Endocrinol Metab; 1993 Jun 17; 76(6):1446-51. PubMed ID: 8501149
    [Abstract] [Full Text] [Related]

  • 20. Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas.
    Porcellini A, Ciullo I, Pannain S, Fenzi G, Avvedimento E.
    Oncogene; 1995 Sep 21; 11(6):1089-93. PubMed ID: 7566968
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.